Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$695
Buy Report View Sample

Published: April 30, 2020 Report Code: GDHCHT087-ST

Select Item

This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.

Scope

This 32-page report gives important, expert insight you won’t find in any other source. 11 tables and 9 figures throughout the report illustrate major points and trends. This report is required reading for:

• Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months

• Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.

• Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.

Reasons to Buy

Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease

Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area

Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic

Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment

4d Molecular Therapeutics
Adlai Nortye Biopharma Co Ltd.
AIVITA Biomedical
Inc.
Akouos Inc
Alexandria Venture Investments
Aligos Therapeutics Inc
ALX Oncology Inc
Amal Therapeutics SA
Annexon
Inc
Ansun BioPharma Inc
Antiva Biosciences
Apexigen
Inc.
Aqualung Therapeutics Corp
ARCH Venture Partners LP
ARS Pharmaceuticals
Inc.
Ascentage Pharma group
Atomwise Inc.
Biopact Cellular Transport Inc
Blueberry Therapeutics Ltd.
Boxer Capital
BW Therapeutics LLC
Cadent Therapeutics
Carisma Therapeutics Inc.
Casdin Capital LLC
Casma Therapeutics
Inc.
Celsense Inc
CerFlux Inc
Chondrial Therapeutics LLC
Cormorant Asset Management LLC
Cowen Healthcare Investments
Decibel Therapeutics
Inc.
Deerfield Management
ElevateBio LLC
Emulate Inc.
EQRx Inc
Escient Pharmaceuticals
Inc.
Evox Therapeutics Ltd
Fidelity Management & Research
Foresite Capital Management LLC
Freeline Therapeutics
Galecto Biotech AB
Galera Therapeutics Inc
Generation Bio Corp
Heartseed Inc
Horama SA
Hotspot Therapeutics
Inc
Hoverink Biotechnologies Inc
ILiAD Biotechnologies
LLC
Immune-Onc Therapeutics
Inc.
Immunocore Ltd
Impact Therapeutics
InCarda Therapeutics
Inc.
InSightec Ltd
Intarcia Therapeutics Inc
Intensity Therapeutics
Inc.
iTeos Therapeutics SA
KAHR medical Ltd
Kaitai Capital
Kallyope Inc
Kleo Pharmaceuticals Inc
Ksq Therapeutics
Inc
Kymera Therapeutics LLC
Lilly Asia Ventures
Max Biopharma Inc
Medicxi Ventures (UK) LLP
Metacrine
Inc.
Minoryx Therapeutics
Modalis Therapeutics Corporation
Nanjing Legend Biotech Co Ltd
NBE-Therapeutics AG
Neuraly
Inc
Neurana Pharmaceuticals
Inc.
Neurotez Inc
NMD Pharma ApS
Nohla Therapeutics
Inc.
Novo Holdings AS
Oncoheroes Biosciences Inc
OncoResponse
Inc.
Orasis Pharmaceuticals
Orbimed Advisors LLC
Partner Therapeutics
Inc
Perceptive Advisors
Phylos Bioscience Inc
Pliant Therapeutics Inc
Polaris Partners LLC
Quentis Therapeutics
Inc.
RA Capital Management LLC
Rakuten Medical Inc
Rallybio
LLC
ReAlta Life Sciences Inc
Redmile Group LLC
Relay Therapeutics
RemeGen Ltd
Rgenix
Inc
Rheos Medicines
Inc.
Ripple therapeutics Corp
Rongchang Bio-Pharmaceutical Co.
Ltd
Sen-Jam Pharmaceutical LLC
Senti Biosciences
Inc
Sirnaomics
Inc.
Slayback Pharma LLC
SQZ Biotech
StemBioSys Inc
Surveyor Capital Ltd
SutroVax Inc
Synthego Corporation
Tecnologia Regenerativa Qrem SL
Transcenta Holding Ltd
Vedanta Biosciences
Inc.
Velicept Therapeutics
Inc.
Vivo Capital LLC
Xilio Therapeutics Inc
XtalPi
Inc.

Table of Contents

1 Executive Summary

2 Table of Contents

3 Venture Capital Trends

4 Investors in Biopharmas

5 Regional Breakout

6 Companies with Venture Capital at Risk

7 Key Findings

8 Appendix

Frequently asked questions

Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals thematic reports
Currency USD
$695

Can be used by individual purchaser only

Most Popular
$1,390

Can be shared by unlimited users within one corporate location e.g. a regional office

$2,085

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals in real time.

  • Access a live Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more